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PATIENT DERIVED XENOGRAFT MODELS OF SMALL-CELL LUNG 
CANCER PROVIDE MOLECULAR INSIGHTS INTO MECHANISMS OF 
CHEMOTHERAPY CROSS-RESISTANCE 
DAVID T. MYERS 
 
ABSTRACT 
 
Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor 
with a 5% survival rate over 5 years. Though SCLC comprises 13% of all cases of lung 
cancer the median survival time of 14.5 months has seen little improvement over the last 
four decades.  Standard treatment relies on DNA damaging agents such as 
Cisplatin/Etoposide (EP) which induce a high response rate of 60-70%. Despite this 
initial response, nearly all patients will relapse rendering first-line therapies ineffective.  
Furthermore, SCLC has been shown to develop chemotherapy cross-resistance in which 
resistance to first-line chemotherapies will confer resistance to additional DNA damaging 
agents thereby reducing treatment efficacy and duration of response. Cross-Resistance 
constitutes a major clinical issue whose underlying mechanisms remain a mystery.  
 The modest improvements in SCLC patient outcomes over the decades may be 
partially explained by the existing systems of study. Current methodologies of SCLC 
study rely on cell lines, patient samples, and Genetically Engineered Mouse Models 
which have little functional correlation to clinical outcomes. While few sources have 
proposed Patient Derived Xenograft (PDX) systems as an improved alternative, 
significant data remains sparse. Without a robust model system which accurately 
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recapitulates patient outcomes, molecular pathways driving resistance cannot be 
uncovered. Here we present the generation of 34 SCLC PDX models which maintain 
both genomic and functional fidelity. Furthermore, treatment of a 30-model subset with 
first-line chemotherapy EP and a novel chemotherapy Olaparib/Temozolomide (OT) 
allowed for functional and molecular comparison between groups. Our findings 
demonstrate incomplete independent resistance mechanisms between EP and OT 
treatment with a small overlap of 31 genes involved in glycolysis and xenobiotic 
metabolism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vii 
 
TABLE OF CONTENTS 
 
 
 
TITLE…………………………………………………………………………………….i 
 
COPYRIGHT PAGE…………………………………………………………………….ii 
 
READER APPROVAL PAGE………………………………………………………….iii 
 
ACKNOWLEDGEMENTS…………………………………………………...………...iv 
 
ABSTRACT……………………………………………………………………………..v 
 
TABLE OF CONTENTS……………………………………………………….………vii 
 
LIST OF TABLES……………………………………………………………………...ix 
 
LIST OF FIGURES…………………………………………………………….………x 
 
LIST OF ABBREVIATIONS…………………………………………….……………xi  
 
INTRODUCTION………………………………………………………………….......1 
 
SMALL CELL LUNG CANCER: EPIDEMIOLOGY AND PATHOLOGY…1 
 
SCLC MODEL SYSTEMS…………………………………………………….3 
 
ACCURATE STUDY OF SCLC CROSS-RESISTANCE……………………6 
 
SPECIFIC AIMS……………………………………………………………………....9 
 
METHODS……………………………………………………………………………10 
 
SCLC PATIENT SAMPLE COLLECTION…………………………………10 
 
DEVELOPMENT OF PDX MODELS……………………………………….11 
 
PATHOLOGICAL AND IMMUNOHISTOLOGICAL ANALYSIS………..12 
 
RNA SEQUENCING IN EP-TREATED MODELS…………………………13 
 
 
viii 
 
IN VIVO TREATMENT DATA COLLECTION……………………………14 
 
RESULTS…………………………………………………………………………….17 
 
GENERATION OF A SCLC PDX LIBRARY………………………………17 
 
FUNCTIONAL ANALYSIS OF PDX MODELS IN  
RESPONSE TO EP…………………………………………………………..22 
 
MOLECULAR CORRELATES OF RESISTANCE  
IN EP TREATED PDX MODELS…………………………….…………….26 
 
FUNCTIONAL ANALYSIS OF PDX MODELS  
IN RESPONSE TO OT……………………………………………………...29 
 
FUNCTIONAL AND MOLECULAR CHARACTERISTICS  
IN A 30 MODEL OT-TREATED PDX COHORT…………………………32 
 
DISCUSSION……………………………………………………………………….37 
 
GENERATION OF PDX MODELS………………………………………..37 
 
FUNCTIONAL FIDELITY OF PDXs…………………………...…………38 
 
MOLECULAR DETERMINANTS OF  
CHEMOTHERAPY RESISTANCE………………………………….…….40 
 
CHEMOTHERAPY CROSS-RESISTANCE……………….……...………41 
 
REFERENCES………………………………………………………………………46 
 
CURRICULUM VITAE…………………………………………………………….55 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
LIST OF TABLES 
 
 
Table 1:                          PDX Development Statistics                                           20 
 
Table 2:  EP Treated PDX Gene Set Enrichment      27 
 
Table 3:  30 Model PDX Tumor Responses to OT Treatment    34 
 
Table 4:  31 Genes Associated with EP and OT Resistance                36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
x 
 
LIST OF FIGURES 
 
Figure   Title            Page 
 
   1                                Collection of SCLC Patient Samples                                         
           and PDX Development                                      19 
 
   2                           PDX Development and Molecular Fidelity                     21    
 
   3                                SCLC PDX Models Reflect Patient Outcomes                          
                                     for First-line Chemotherapy                25 
 
   4                               Systematic Analysis of Gene Transcription vs.                           
                                    EP Response                                       28 
 
   5                               SCLC PDX Models Recapitulate Patient Clinical                       
                                    Response to Olaparib + Temozolomide          31 
 
   6             EP versus OT Response in 30 Model PDX Cohort                      35 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xi 
 
LIST OF ABBREVIATIONS 
 
ALK    --  Anaplastic Lymphoma Kinase Oncogene 
 
CP   --  Carboplatin + Etoposide 
 
CT    --  Computer Tomography 
 
CTC   --  Circulating Tumor Cell 
 
DNA    --  Deoxyribonucleic Acid 
 
EGFR    --  Epidermal Growth Factor Receptor Oncogene 
 
EP    --  Cisplatin + Etoposide 
 
ES-SCLC   --      Extensive Stage Small Cell Lung Cancer 
 
GSEA   --  Gene Set Enrichment Analysis 
 
GEMM   --  Genetically Engineered Mouse Model 
 
IACUC  --  Institutional Animal Care and Use Committee 
 
KRAS   --     Kirsten Rat Sarcoma Oncogene 
 
LS-SCLC   --  Limited Stage Small Cell Lung Cancer 
 
MGH   --  Massachusetts General Hospital 
 
NSCLC  --  Non-Small Cell Lung Cancer 
 
NSG   --  NOD scid Mouse 
 
OT    --  Olaparib + Temozolomide 
 
PDX   --  Patient Derived Xenograft 
 
PET   --  Positron Emission Tomography 
 
Rb   --  Retinoblastoma Tumor Suppressor Gene 
 
 
xii 
 
 
RNA   --  Ribonucleic Acid 
 
SCLC     --  Small Cell Lung Cancer 
 
TF   --  Transcription Factor 
 
 
 
1 
 
 
 
INTRODUCTION 
 
 
SMALL CELL LUNG CANCER: EPIDEMIOLOGY AND PATHOLOGY 
 
Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with 
a 5-year survival rate of 5% and little improvement in prognosis over the last three 
decades.1-4 This common malignancy comprises 13% of all lung cancer cases and affects 
33,000 people per year in the United States alone.5-6 Pathologically, it is differentiated 
from other non-small cell lung cancer (NSCLC) by its neuroendocrine phenotype, rapid 
growth rate, and propensity for early and widespread dissemination.7-8 SCLC 
demonstrates a significantly faster doubling time of 86.3 days compared to 166.3 days for 
all lung tumors.9 While age and heavy tobacco use are the highly significant risk factors, 
this cancer will also affect non-smokers at a rate of 1-2%.10-11 Patients typically present 
with localized symptoms such as cough (50%), dyspnea (40%), and chest pain (35%).6 
However, due to the rapid growth and dissemination of SCLC, patients often also present 
with symptoms such as weight loss (50%), weakness (40%), and anorexia (30%) as a 
result of multiple metastatic lesions.6,12-13  
From a clinical perspective, the standard Classification of Malignant Tumors 
(TMN) system normally used to rate and stage tumors is of relatively low utility as the 
cancer has almost always spread beyond the primary lesion by the time of diagnosis.  
Instead, SCLC is designated as limited-stage (LS-SCLC) where the primary lesion has 
spread only to few localized lymph nodes, or extensive-stage (ES-SCLC) where the 
cancer has invaded multiple peripheral sites.  Only a fraction of LS-SCLC is considered 
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curable, and ES-SCLC is considered incurable. The aggressive and undifferentiated 
nature of even localized disease often disqualifies patients as candidates for surgical 
resection in sharp contrast to other forms of lung cancer.14-15 While certain limited-stage 
cases may be amenable to surgery, current studies have demonstrated that surgical 
resection has no significant impact on prognosis and the practice remains controversial.16  
The molecular complexities of SCLC provide an additional barrier to treatment 
with targeted molecular therapeutics. Other forms of lung cancer, such as Non-Small Cell 
Lung Cancer (NSCLC), are typically associated with aberrant cell signaling due to 
oncogenic driver mutations in genes such as KRAS, EGFR, or ALK. Thus, the inhibition 
of overactivated cell signaling pathways have provided a therapeutic window for 
treatment of NSCLC. In contrast, the most common mutations in SCLC are the loss of 
the RB1 and TP53 tumor suppressors, and therapies have not yet been developed to target 
these mutations.17-23 Instead, treatment of SCLC relies on the use of DNA damaging 
agents to destroy the rapidly growing tumors, a method that remains largely unchanged 
since its first use more than three decades ago.24-25 The initial detection and further 
evaluation of efficacy of treatment is measured be serial radiographic presentation 
followed by additional CT and PET scans to detect any distant metastases. By this 
measure, SCLC has been shown to be highly responsive to first line chemotherapies with 
an objective response rate seen in 66-67% in patients receiving either carboplatin or 
cisplatin respectively and up to 70% with cisplatin in combination with etoposide.26 This 
initial response rate is approximately double that of NSCLC to first-line chemotherapy. 
The most commonly used first line therapy for SCLC consists of 4-6 cycles of a 
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platinum-containing agent, either cisplatin or carboplatin plus etoposide (EP). EP has 
been shown to be more effective and tolerable than other first-line regimens with a 
median survival time of approximately 14.5 months in cases of LS-SCLC.27 Despite this 
initial success, nearly all SCLC patients will eventually develop drug resistance rendering 
the first line treatment ineffective. Clinical prognoses of post-relapsed patients are 
primarily determined by the tumor sensitivity following first line therapy.  Patients who 
relapse within 90 days of the end of treatment are considered to be “chemo-resistant” 
while patients relapsing after 90 days post-treatment are considered “sensitive”.  These 
designations of sensitive or resistant tumor phenotypes have been shown to be well 
correlated with future tumor prognosis.27 Perhaps most concerning in SCLC, is that this 
developed resistance to first line therapies translates into resistance to other 
chemotherapeutic agents. Post-relapse patients receiving second line therapy show 
response rates of less than 30% with a shorter benefit which correlates with the duration 
of benefit following EP.27 Chemotherapy cross-resistance makes relapsed SCLC difficult 
to treat with additional therapies and helps explain why median survival time has not 
increased significantly since its first characterization. 
 
  
SCLC MODEL SYSTEMS 
 
To date, the discovery of novel therapeutic strategies has remained stagnant with 
median survival times failing to improve significantly over the last four decades despite a 
decreasing trend in SCLC occurrence, likely as a result of a decline in smoking.28-29 
While combination therapies such as cisplatin/etoposide have seen some beneficial 
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effects, these improvements pale in comparison to the exceedingly low 5-year survival 
rate.26 This slow trend in scientific progress may be partially explained by the methods 
and technologies used to examine this cancer in a laboratory setting.  Current methods for 
studying SCLC primarily rely on Genetically Engineered Mouse Models (GEMMs), 
individual patient samples, or long established in vitro models and each has significant 
limitations.30-32 While GEMMs may be able to mimic specific genetic alterations found in 
SCLC such as the loss of TP53 or Rb1 they cannot account for currently unknown 
genetic determinants or individual differences in patients, and tumorigenesis in this 
model does not reflect environmental factors such as smoking. Regarding human SCLC, 
limited opportunity for surgical resection or repeat biopsy presents a significant barrier to 
obtaining new samples for study.  
Established cell lines of SCLC also have significant limitations. They often lack 
detailed and accurate patient history thereby obscuring which molecular features stem 
from the original patient tumor. Even with an accurate patient history the process of 
establishing a stabilized cell line creates the potential for bottleneck effects or selective 
fitness within an in vitro environment.33-35 A recent comprehensive study of established 
SCLC lines captured this problem by demonstrating that in vitro responses to 
chemotherapy did not reflect the donor patient responses.36 
Without a robust and comprehensive model system that reflects the response of 
the human disease to standard therapies, the mechanisms underlying cross-resistance 
remain elusive.  Patient Derived Xenograft Models (PDX) of SCLC may hold some 
promise. PDX models are an in vivo system in which patient tumor samples are 
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implanted into immunocompromised mice and propagated into subsequent mice for 
testing of therapeutic agents.37 A recent report suggests that they have a better correlation 
with clinical outcomes, although only four distinct models were studied.38 Though 
limited in scope, these initial findings provide some hope that in vivo models may be a 
more accurate system for recapitulating clinical responses. Furthermore, careful 
monitoring of passage number and molecular sampling at each passage allows continuous 
tracking of any molecular incongruencies between the model and original patient sample. 
It is important to note that while PDXs may have potential as a model system for 
SCLC translational research, certain limitations in development of these models need to 
be overcome, and the potential fidelity of these models to the molecular and functional 
characteristics of patient tumors needs to be assessed.  
The limited opportunity for surgical resection or biopsy in SCLC presents a 
unique challenge to the acquisition of required patient tissues. However, many tumors are 
known to shed cells into the bloodstream as part of the process of seeding additional 
metastatic sites. Multiple studies have confirmed a high abundance of circulating tumor 
cells (CTC) in the blood of SCLC patients, consistent with the ability of SCLC to 
disseminate rapidly throughout the body.39-40 While the high volume of CTCs in the 
blood confers a poor prognosis it also enables the collection of these cells through non-
invasive blood draws.41-42 At the present time, only a small handful of SCLC PDX 
models have been generated by collection of patient CTCs.  While these models have 
been shown to correlate with the clinical outcome of the patients form which they were 
derived the small number of samples places a statistical limit on translational power.38 
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Furthermore, the loss of TP53 and RB1, nearly universal in SCLC, may result in 
significant genomic instability and tumor evolution between sequential passages into 
mice.37, 43 In the limited number of CTC-derived PDX models of SCLC in existence, 
genomic alterations appear to acutely reflect patient baselines; however, like clinical 
responses the current data is limited by scope. Generally, further development and 
subsequent investigation of PDX models is required before the advantages of these in 
vivo systems can be experimentally confirmed. 
 
  
 
ACCURATE STUDY OF SCLC CROSS-RESISTANCE 
 
Arguably the critical measure of success for a model system for SCLC 
translational research is its ability to reveal factors that influence the emergence of drug 
resistance. Initial sensitivity to chemotherapy almost always gives way to relapse, and the 
mechanisms of drug resistance remain a mystery. This issue is further compounded by 
the clinically observed phenomenon of chemotherapy cross-resistance which limits the 
potential for remission from additional therapies. Cisplatin/Carboplatin and Etoposide act 
as anti-tumor agents by significantly damaging the more susceptible DNA of rapidly 
dividing tumor cells.1 Cisplatin works to create molecular crosslinks in DNA disrupting 
its normal molecular structure, while Etoposide acts by inhibiting Topoisomerase 
proteins which would otherwise reduce physical stress on DNA. Most second line 
therapies also act by inducing DNA damage, and therefore may be limited in their ability 
to kill cancer cells due to the advent of cross-resistance. It is however, unclear what 
elements of a drug’s mechanism of action make it susceptible to this limited efficacy.  
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While many approved drugs such as Topotecan, Irinotecan, and anthracyclines and 
antimetabolites have been prone to cross-resistance mechanisms, it is still uncertain if 
newer DNA damaging regimens will be equally susceptible, especially those which pair a 
DNA damaging agent with an inhibitor of DNA repair, such as Olaparib (PARP1/2 
inhibitor) and Temozolomide (Guanine alkylating agent).44-51 
In order to better explore the molecular underpinnings of resistance, accurate 
disease modeling is a necessity. Models of SCLC including GEMMs, patient samples, 
and in vitro cell lines have been shown to be limited in their ability to translate clinically, 
and while PDX models hold theoretical advantages, this has yet to be demonstrated in a 
statistically significant manner. Assessment of a robust PDX model system with 
translational potential would include both functional and genomic congruence to patients 
in the clinic; the in vivo system should be able to adequately reflect clinical trends of 
tumor growth under treatment as well as recapitulate the genomic landscape from which 
they were derived. Both of these measures would ensure that any changes in tumor 
growth or transcription within the model will mirror changes occurring in the tumors of 
patients.  Establishment of such a system would provide a platform for testing of 
chemotherapy responses and cellular processes associated with resistance to these 
therapies.  
Presented here is a system for the efficient generation of SCLC PDX models.  
Patient tissue from the clinic from acquired biopsies and CTCs has generated 34 
established SCLC PDX models which significantly mirror the histological and genomic 
characteristics of their clinical counterparts.  Furthermore, these models were treated with 
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standard first line therapy EP as well as the experimental DNA damaging agents OT.  
Evaluation of tumor responses to EP in vivo not only reflected patient outcomes but was 
able to distinguish tumors from treatment naïve and post-relapse sources. Model 
responses to OT treatment were not as clear cut, showing both sensitive and resistant 
phenotypes which were only trending towards correlation to EP treatment status. In line 
with tumor metrics, gene expression analysis of EP and OT treated models showed some 
overlapping trends in resistance mechanisms supporting tumor response of incomplete 
cross-resistance. This study emphasizes the ability of PDX models to accurately predict 
clinical outcomes to chemotherapies and demonstrates the potential for the novel therapy 
OT to overcome certain molecular methods of cross-resistance. 
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SPECIFIC AIMS 
 
 While first-line chemotherapies have demonstrated high response rates in the 
treatment of SCLC, the emergence of drug resistance ultimately renders initial relapse 
irrelevant as drug-resistant tumors stop responding to therapy before the patient is cured.  
Furthermore, the development of resistance to first line therapies also conveys cross-
resistance to additional DNA damaging agents thereby limiting both duration of response 
and efficacy of treatment. Current methodologies for study of SCLC such as cell lines, 
patient samples and GEMMs have shown little correlation with clinical patient outcomes, 
placing additional barriers to the discovery of clinically effective treatments. While some 
patient derived xenograft (PDX) in vivo models have been shown to accurately mimic 
behavior of other cancers in the clinic, the evidence of such in SCLC remains 
unexamined and the underlying mechanisms of chemotherapy cross-resistance remain 
elusive. 
 The aim of this investigation was two-fold.  First, a high efficiency system for the 
generation SCLC PDX models from patient samples was utilized to assess whether in 
vivo models can accurately represent the genomic and functional features of SCLC 
tumors in the clinic. Second, this PDX system was subjected to a novel chemotherapy 
regimen as part of a co-clinical trial at MGH evaluating clinical patient efficacy in 
parallel with tumor responses of post-relapse models. This in vivo testing schema allowed 
for further investigation into the underlying molecular features of resistance to first-line 
and novel chemotherapy regimens in hopes of finding commonalities between the two. 
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METHODS 
 
SCLC PATIENT SAMPLE COLLECTION 
Collection of CTCs were derived from patients at Massachusetts General Hospital 
(MGH) with known or suspected cases of SCLC who voluntarily enrolled in the 
approved IRB protocol “Collection of peripheral blood samples from patients with solid 
tumors for circulating tumor cell analyses” (Protocol # 05-300, Dana Farber/Harvard 
Cancer Center). This protocol dictated that during routine blood draws an extra 15-20 mL 
was drawn into two room temperature EDTA vacutainer tubes (7.5-10 mL each).  
Following whole blood collection, samples were immediately transported from the clinic 
at the MGH main campus to the research laboratory. Additional collection of non-CTC 
tissue was provided by informed patient consent for the IRB-approved protocol 
“Collection of specimens and clinical data from patients with known or suspected solid 
tumors (Protocol # 13-416, Dana Farber/Harvard Cancer Center). For this protocol extra 
core biopsy samples from necessary clinical procedures were collected and stored in 
tubes containing 20-40 mL sterile RPMI with 10% Fetal Bovine Serum (FBS). These 
samples were placed on ice and transported from the MGH main campus to the research 
laboratory as quickly as possible. Additional non-biopsy samples were collected from 
pleural or pericardial effusions and were transported in the original collection containers 
to the research laboratory at room temperature. Effusions were concentrated for cellular 
collection via centrifugation, depleted of red blood cells using lysis buffer (BioLegened 
RBC lysis buffer), and depleted of leukocytes with the use of anti-CD45 microbeads 
(Miltenyi Biotec). 
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Peripheral whole blood samples underwent additional processing for the isolation 
and concentration of CTCs. Use of CTC-iChip technologies was the designated primary 
method for collection and concentration of SCLC CTCs from blood samples when 
available.  In the event these technologies were unavailable, blood samples of 10 mL 
were incubated in 500 μL RosetteSep Cocktail (Stem Cell Technology).  Following 20 
minutes of continuous shaking, samples were dilute in a 1:10 ratio with RPMI medium 
1640 (Gibco) in HBSS (Life Technologies) and spread atop a 15 mL Ficoll-Paque Plus 
gradient layer (GE Healthcare). To isolate live cells this gradient was centrifuged at 
1200g for 30 minutes at 18o Celsius. Live cells at the gradient interface were collected 
and washed with 50 mL Phosphate Buffered Saline (PBS).  
 
DEVELOPMENT OF PDX MODELS 
 
Following isolation and enrichment, CTCs were resuspended in a cold solution of 
100 uL HITES media (RPMI, 10nm hydrocortisone, 5 ug/mL insulin, 10 ug/mL 
transferrin, 10 nM B-estradiol, 30 nM Sodium selenite, 2% FBS) mixed with 100 uL 
Matrigel (Corning) and taken up into a 25-gauge syringe on ice. The sample was then 
injected subcutaneously into the right flank of an NSG (NOD. Cg-Prkdcscid 
II2rgtm1Wjl/Szj, Jackson Laboratories) mouse as soon as possible. All animal procedures 
were performed in accordance with Institutional Animal Care and Use Committee 
(IACUC) approved protocols under MGH guidelines. Mice were monitored on a weekly 
basis for tumor development and any subcutaneous palpations were measured over the 
skin with electronic calipers. Tumor volume was calculated by the spheroid formula 
(Volume = π/6 x Length x Width x Width) and tumor-bearing mice were euthanized 
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when volume reached approximately 1500-2000 mm3. Mice bearing the initial patient 
sample were designated as “P0” while subsequent passages of the xenograft followed 
sequential numbering (“P1”, “P2”, etcetera). Following resection and scalpel dissection, 
xenografts of approximately 5-15 mm3 were passaged into additional NSG mice via 
subcutaneous implants.  The remainder of xenograft tissue fragments were collected for 
cryopreservation as well as pathological and molecular analysis. Cryopreservation of 
samples involved collection of fragments in tubes containing 1.3 mL ACL4 media 
(Gibco), 10% DMSO, 10% FBS, and 500 u/mL heparin (Sigma) with slow cooling at a 
rate of 1o Celsius per hour until eventual long-term storage in liquid nitrogen. Tissue 
obtained from tumors for pathological analysis were fixed in 10% neutral buffered 
formalin for 24 hours prior to dehydration in 70% ethanol and embedded in paraffin 
following 24 hours in ethanol. Tumor fragments utilized for molecular analysis were 
flash frozen in liquid nitrogen within 5 minutes of whole tumor resection and stored long 
term in liquid nitrogen.  
 
PATHOLOGICAL AND IMMUNOHISTOLOGICAL ANALYSIS 
 
Fixed and embedded patient and xenograft samples were sliced into 5 um sections 
and stained with hematoxylin and eosin in combination as well as antibodies targeting 
chromogranin (RTU, Leica Biosystems, Buffalo Grove, IL), synaptophysin (RTU, Leica 
Biosystems, Buffalo Grove, IL), CD56 (RTU, Leica Biosystems, Buffalo Grove, IL), 
CD45 (RTU, Leica Biosystems, Buffalo Grove, IL), and Rb (1:200, Biocore, Pacheco, 
CA). Classification of samples was performed under guidance of the WHO Classification 
system for Lung, Pleura, Thymus, and Heart.52 Diagnosis of SCLC was rendered by 
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diffuse cytoplasmic expression of chromogranin, synaptophysin, and CD56 without 
expression of CD45. Differentiation of tumor cells amongst intercalated stromal cells was 
defined by a complete lack of nuclear expression due to loss of Rb expression apparent in 
nearly all cases of SCLC.  
 
RNA SEQUENCING IN EP-TREATED MODELS 
 
Tissue from EP-treated PDX models was homogenized and total RNA was 
extracted using 1mL TRIzol reagent (Life Technologies). Following RNA extraction, 0.2 
mL of chloroform was added to the lysate to allow for phase separation during 
centrifugation. Using cold isopropanol RNA was precipitated from the solution and 
washed with 80% ethanol before further centrifugation and resuspension in nuclease-free 
water. To eliminate DNA the solution was treated with DNAse (Qiagen) and RNA was 
isolated with an RNeasy mini prep kit. The resulting isolated RNA was assessed using an 
Agilant 2100 Bioanalyzer and further processed into cDNA libraries using the Kapa 
Stranded RNA-seq kit with RiboErase HMR.  These samples were then sequenced on 
NextSeq 500 for single end 75 base pair sequencing.  
To eliminate the possibility of overlapping reads from both mouse and human 
tissue, single end reads were simultaneously mapped to the human (hg19) and mouse 
(mm9) reference genome using BBsplit from BBmap. Only reads which were exactly 
matched to the human sequences were further examined. This subset of transcripts were 
then re-mapped to the human reference genome using STAR (v2.5.1b_modified) and 
counts for each read were estimated by Kallisto (v0.43.1).  The parameters for mapping 
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onto the reference genome included ‘—fragment-length 200 and -sd 20’ and gene 
expression was quantified as Transcripts per Million (TPM).  
After the isolation and quantification of human transcripts, hierarchal analysis 
was performed to identify gene sets associated with EP response. For this Gene Set 
Enrichment Analysis (GSEA) only Hallmark gene sets were used (MSigDB v6.0) for all 
genes which correlated with EP response (Spearman p > 0.6). From here further 
examination of MYC target sets (False Discovery Rate < 0.01, 14 total genes) were 
combined to form a small MYC regulon.  The ranked leading edge (n=200) was analyzed 
by Enrichr 53 for genes that positively correlated with the aggregated regulon score in 
order to identify enrichment for ENCODE ChIP-seq datasets. The enrichmed MYC- (and 
its co-factor MAX-) datasets were then further validated by comparison to other profiled 
transcription factors (TFs). For each TF (n=181) a Kolmogorov-Smirnov statistic 
hypothesizing the true distribution ranking of TF is greater than the null distribution. 
Additionally, TF z-scores were calculated based on the Kolmogorov-Smirnov distribution 
associated p values. Finally, the small MYC regulon was combined with genes from the 
leading MYC and MAX datasets (False Discovery Rate < 0.01) to create a Large MYC 
regulon. 
 
 
IN VIVO TREATMENT DATA COLLECTION 
 
For each tested PDX model, tumor resections from mice P3 or P4 were implanted 
subcutaneously into the right flank of 4-5 male NSG mice and allowed to grow 
uninterrupted to a volume of 400-600 mm3.  Treatment with cisplatin/etoposide (EP) 
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consisted of 3-5 mice while vehicle treatment was performed in 1-2 mice. The treatment 
protocol included cisplatin at 7 mg/kg dissolved in 0.9% saline and administered via 
intraperitoneal injection on days 1 and 8. Concurrent to cisplatin treatment, etoposide at 
10mg/kg dissolved in a 12.5:1 ratio of 0.9% saline + 0.1% citric acid to N-methyl-2-
pyrrolidone (NMP) and administered via intraperitoneal injection on days 1-3 and again 
on days 8-10. Treatment with Olaparib/Temozolomide (OT) followed the same mouse 
treatment and control arms as well as untouched initial tumor growth.  Drug protocol 
consisted of Olaparib at 50 mg/kg dissolved in PBS (pH 7.4) + 10& 2-hydroxypropyl-
Beta-cyclodextrin delivered via oral gavage twice daily at 10 hours for 5 continuous days. 
Alongside Olaparib treatment, Temozolomide at 25 mg/kg dissolved in PBS (pH 7.4) + 
1% carboxymethylcellulose was administered via oral gavage once daily for 5 continuous 
days. 
At the start of each drug regimen tumors were measured 2-3 times weekly and 
tumor volume was calculated by the spherical volume mentioned previously. Tumor 
metrics were defined by TTP (time to reach 200% initial tumor volume since start of 
treatment) and by best response (maximum percent change in initial tumor volume seen 
between days 14-28). The definitive TTP and best response for each PDX model 
consisted of the averaged values for all treated mice. The endpoint for measurements of 
these mice were defined as the TTP or 80 days elapsed since the start of treatment. As an 
additional control, undrugged mice were measured and tumor doubling time (Tdbl) was 
calculated with at least 3 measurements within the approximate window of logarithmic 
growth between 200-1500 mm3. Tumor growth was modeled exponentially with 
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equations fit to the growth curve for each model using GraphPad Prism and averaged. 
Due to variations in PDX model growth curves, TTP was corrected for intrinsic doubling 
time using a simple ratio of TTP/Tdbl. 
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RESULTS 
 
 As a foreword to the following results section it is important to be clear as to 
which components of the data and analysis are the direct result of the author and which 
are generated from numerous collaborators on this project. It should be stressed that in no 
way is all the data presented here a result of a single effort by the author over the course 
of a year but rather a compilation of many years work across multiple groups.  The data 
which is specific to the author includes all in vivo work specifically the PDX generation, 
in vivo drug treatment, tumor measurements and associated data analysis.  Additional 
components were the hard work of others in the MGH Cancer Center or collaborators 
from additional institutes and includes histology/pathology, Whole exome sequencing, 
RNA-sequencing, ChIP-Seq datasets, clinical enrollment, and overall project 
methodology/development.  
 
GENERATION OF A SCLC PDX LIBRARY  
 
Current methods employed for studying SCLC including cell lines and GEMMs 
have led to only modest improvements in patient outcomes despite decades of research. 
While the use of PDX models may hold several advantages, to date, production of these 
models has been limited.  The results outlined here provide details on the efficient 
generation of SCLC PDX mouse models, which may be used to better understand the 
molecular mechanisms underlying drug resistance.  
Tumor samples were collected from known or suspected cases of SCLC treated at 
MGH. Circulating tumor cells (CTCs) were isolated from the blood samples via CTC-
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iChip devices41, and tissue cores and malignant effusion samples were obtained from 
patients undergoing procedures for other clinical purposes (Figure 1). Importantly, these 
CTC iChip devices represent a novel system developed by members of the MGH Cancer 
Center to isolate CTCs from whole blood samples and are a significant step forward not 
only in the generation of PDX models but for numerous additional in the study of cancer.  
From June 2014 to June 2016, 42 blood samples were processed using the CTC iChip. 
From these samples,16 mice developed palpable subcutaneous tumors providing an 
overall tumor production rate of 38% (95% CI) with an average latency of 115 days. An 
additional model was derived from CTCs isolated manually by Ficoll density gradient.20 
Of the 18 tissue samples collected via biopsy cores during the same interval, 16 of such 
samples developed tumors leading to a success rate of 89% (CI 95%) and an average 
latency of 78 days.  Finally, one PDX model was successfully generated from a 
malignant pleural effusion (Table 1). Overall, 34 SCLC PDXs were established from 27 
patients with a range of clinical disease progression. Of these 27 patients, 15 models were 
developed from patients prior to receiving any therapy, 19 models were developed from 
patients with at least one line of therapy, and 3 models were developed from patients over 
multiple time points during their course of treatment (Figure 2A). 
To confirm the generated tumors were in fact SCLC, histological and 
immunohistochemical analysis of xenografts was performed by a thoracic pathologist and 
compared to patient biopsies when available (Figure 2B).  In all established PDX models 
examined, pathological features were demonstrated to be consistent with SCLC, and 
individual models were shown to closely correspond with original patient biopsies. 
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Furthermore, in a separate analysis, a subset of PDX models underwent whole exome 
sequencing (WES) and were compared with both serial passages and patient biopsies to 
assess genomic fidelity. RNA sequencing was also performed and compared between 
passages to assess whether there was evolution of the transcriptome.  The results of these 
analyses also showed a high correlation between PDX models and patient tumor 
genomics with minimal genetic drift over subsequent passages (Figure 2C-D).
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FUNCTIONAL ANALYSIS OF PDX MODELS IN RESPONSE TO EP 
 
The generation of a PDX library which accurately resembles patient tumors from 
a pathological standpoint is critical for model validation; however, the translational 
potential of these PDXs is also dependent on the functional response of these tumors to 
therapy. Among 63 established cell lines of SCLC, there has been no good correlation 
between cell line exposure (or lack of exposure) to chemotherapy and in vitro sensitivity 
to these same therapeutics (Figure 3A). The limited ability of cell lines to accurately 
recapitulate clinical patient outcomes underscores the need for functional fidelity of 
models of SCLC for study. 
In order to understand if PDX models would more accurately reflect patient 
clinical histories, it was questioned whether there is an observed differential response to 
chemotherapy between a PDX obtained before treatment and a PDX obtained after 
treatment in which resistance has been established. This differential response would be 
most impactful if demonstrated between models derived from the same patient before 
treatment and after relapse. For this functional assessment, a regimen of first line 
chemotherapy cisplatin/etoposide (EP) was designed to both shrink sensitive chemo-
naïve tumors and distinguish growth rate of PDX tumors from the same patient before 
and after clinical treatment. The treatment regimen given to PDX mice consisted of 
cisplatin at 7mg/kg delivered via intraperitoneal injection at days 1 and 8 alongside 
etoposide at 10mg/kg delivered orally at days 1,2,3,8,9, and 10. This regimen was 
optimized in paired pre-treatment and post-relapse models to result in tumor shrinkage in 
the EP-naive model but not in the model derived from the same patient following both 
23 
 
 
 
first- and second-line therapy (Figure 3B). This same PDX EP regimen was then applied 
across 30 PDX models, 12 of which were treatment naïve and 18 of which were post-
relapse models.  Xenograft sensitivity to EP was quantified by the maximum depth of 
tumor shrinkage (lowest tumor volume within 14-28 days of treatment) and the time to 
progression (TTP, the number of days required to reach twice the initial tumor volume) 
(Figure 3B). All examined PDX models undergoing EP treatment were performed in 
biological duplicate or triplicate and did not vary significantly between one another 
further demonstrating replicability.  
PDX models from EP-naïve sources were examined against models derived from 
EP-exposed sources following the in vivo EP treatment protocol described earlier. 
Waterfall plots of best response of all models are shown in Figure 3C. Data showed that 
maximum tumor shrinkage was nearly uniform across the EP-naïve models while models 
developed from EP-exposed patients showed a more diverse range of responses. This 
finding is somewhat expected given that patients in the clinic receive a limited number of 
chemotherapy cycles rather than continuous treatment until resistance emerges. 
Therefore, the degree to which resistance emerges in patients will vary just as the rates of 
tumor depth response varies in EP-exposed PDX models. While the measure of TTP was 
higher in EP-naïve PDXs compared to EP-exposed PDXs this data is further complicated 
by individual tumor doubling rates. Different models exhibit different baseline rates of 
growth and thus direct comparison of TTP between groups is limited by individual 
differences. To correct for this, the doubling rates for each model were measured in 
untreated PDXs and the TPP was divided by this intrinsic doubling rate. This corrected 
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TTP (TTPdbl) measure demonstrated a statistically significant difference between the EP-
naïve and EP-exposed tumors (Figure 3D). 
With clear evidence of differential responses to EP within the PDX models further 
evidence was needed to confirm that the responses of individual models mapped onto the 
responses of the patients from which each was derived. Uniform sensitivity or resistance 
of PDX models to EP based solely on binary clinical labels warrants additional 
examination into the subtleties of individual differences of patients. Patient TTP was 
measured as the number of days from the final dose of Cisplatin/Etoposide to the first 
disease progression as concluded by radiography. Given this numerical value it was 
found that response of EP-exposed PDX models were moderately correlated with 
individual responses in patients treated with a first line therapy, despite the numerous 
variables which may affect clinical TTP values (Figure 3D). This finding helps validate 
the ability of PDX models to recreate the clinically observed phenomenon of reduced 
TTP values following first line treatment.  However, clinical TTP data for EP-naïve 
patients was too limited for an accurate comparison with EP-naïve models thereby 
preventing a complete analysis. Holistically, the comparison between PDX models and 
responses of patients from which they were derived seems to establish PDX models as a 
better system for recapitulating functional patient outcomes of first line therapies 
compared to current methods. The fidelity of the PDX library to patient drug exposure 
history suggests that this system can be used to uncover clinically relevant determinants 
of drug resistance. 
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MOLECULAR CORRELATES OF RESISTANCE IN EP TREATED PDX 
MODELS 
 
The challenge in treating SCLC with chemotherapy is not in generating an initial 
response, as the response rates are very high, but rather preventing the near inevitable 
relapse. To tackle this difficult and persistent issue, the molecular mechanisms 
underlying disease adaptation must first be uncovered. Samples collected from untreated 
models for which EP response had been measured were analyzed in order to identify 
potential molecular features associated with chemoresistance.  A subset of 19 PDX 
models from the experiment were chosen for transcriptome sequencing to compare 
baseline gene transcription between experimentally determined EP-sensitive and EP-
resistant models.  
Transcripts within the sequencing dataset were analyzed for correlation to EP 
response by gene set enrichment interrogation using only Hallmark gene sets. These gene 
sets are a curated collection of genes complied from independent databases and are 
associated with specific cellular processes such as DNA repair mechanisms, cellular 
metabolism, mitotic activity, etcetera.  Interestingly, no gene sets were shown to have 
significant positive correlation with EP sensitivity.  However, there was a significant 
association with EP resistance in 10 of these curated sets. Included within these gene 
categories, positive correlation with EP resistance was reflected in genes encoding for 
processes involved in response to reactive oxygen species (ROS), ultraviolet light (UV) 
DNA damage, as well as genes upregulated to enable drug detoxification (“Xenobiotic 
Metabolism”). In addition to these gene groups a small group of 14 were identified as 
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targets of the MYC transcription factor correlated significantly with EP resistance. (Table 
2). 
There is some evidence to suggest that overexpression of the MYC gene in a 
SCLC GEMM model may promote tumor growth in the context of chemoresistance. The 
role of the myc transcription factor in normal cellular function is multimodal and is 
hypothesized to exhibit transcriptional control over a large portion of the genome. To 
further evaluate whether the 14-gene pilot “MYC target” signature represents true MYC-
bound targets, these 14 genes plus an additional 186 with similar expression patterns 
across the PDX models were compared with a library of over 800 ChIP-seq datasets. 155 
of 200 genes were enriched within MYC ChiP-seq datasets, and MYC binding was more 
significantly associated with these 200 genes than binding to other transcription factors 
(Figure 4A-D). This secondary analysis provides support that the upregulation of MYC 
target genes may be a valid indicator of resistance in the context of chemotherapy.  
Though subsequent studies and analysis would be needed, the data presented here merits 
further investigation of a MYC signature as a potential biomarker for chemoresistance in 
patients.  
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FUNCTIONAL ANALYSIS OF PDX MODELS IN RESPONSE TO OT 
 
The ability to accurately model patient outcomes in an in vivo format provides a 
platform on which to inspect tumor responses to additional therapies in the hopes that 
PDX responses can accurately predict clinical responses. One such therapy, 
Olaparib/Temozolomide (OT) is currently under phase I/II clinical trial at MGH. Like 
many current therapies for SCLC, including EP, OT provides an anti-tumor effect by 
inducing DNA damage. Temozolomide damages DNA by methylation/alkylation of 
guanine residues while Olaparib inhibits the PARP1/2 proteins otherwise critical for 
recruitment of DNA damage repair pathways. Though both EP and OT have been shown 
to cause irreparable damage to tumor DNA, their respective mechanisms of action are 
different and thus it is unclear whether tumor dynamics of OT treatment will be 
susceptible to chemotherapy cross-resistance.  
Importantly, one subset of the PDX models established here (MGH 1528) are 
derived from the same patient over multiple timepoints. After receiving multiple different 
treatments, this patient was enrolled in the ongoing clinical phase I/II trial of OT. At the 
time of enrollment this patient had widespread metastatic disease with a particularly large 
left axillary mass. Following treatment with OT this patient showed partial response to 
therapy at day 89 and remained on the study for a total of 6.5 months before ultimately 
progressing (Figure 5A).  PDX models developed from this patient were derived from 
CTCs at two separate timepoints; first, immediately prior to enrollment in the OT clinical 
trial (MGH1528-1) and second, at the time of relapse (MGH1528-2). Results from PDX 
treatment illustrated a dramatic tumor regression in MGH1528-1 mice treated with a 
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single cycle of OT compared to vehicle controls. In contrast, MGH1528-2 PDX models 
created after patient relapse did not respond to OT treatment and instead mimicked 
growth dynamics comparable to baseline or vehicle treated mice of the same origin 
(Figure 5B). Since the start of the phase I/II clinical OT trials an additional 3 patients for 
which 6 PDX models have been established have undergone OT therapy (MGH1518-1B, 
MGH1518-1C, MGH1543-1, MGH1514-5, MGH1518-3). To further assess the 
congruency of the PDX system, these specific models underwent OT treatment as 
discussed above in parallel with the clinical trial. Tumor metrics of the additional OT 
treated mice showed a striking resemblance to clinical outcomes. While more models 
reflecting a similar clinical history and time course need to be evaluated, this initial 
evidence is persuasive that PDX models and associated testing methodology may be able 
to reflect patient responses for a multitude of chemotherapeutic agents.  Additionally, 
data gathered from these models not only bolsters the functional fidelity of this system, 
but also provides the opportunity to compare pathways of resistance between treatments. 
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FUNCTIONAL AND MOLECULAR CHARACTERISTICS IN A 30 MODEL OT-
TREATED PDX COHORT 
 
The development of cross-resistance to chemotherapies in SCLC is a troublesome 
and poorly understood process. Significant evidence has demonstrated that post-relapse 
patients in the context of first line therapy will demonstrate reduced responses to 
additional chemotherapeutic agents. PDX models mirroring clinical outcomes have been 
used here to seek out discrepancies between EP-naïve and EP-exposed sources; however, 
it is unclear whether these transcriptional differences mediate general resistance 
mechanisms or are merely specific to EP treatment.  To further inspect the underlying 
molecular mechanisms at work, the previous 30 model cohort underwent treatment with 
OT and was evaluated for tumor metrics and transcriptional markers. Mice in this cohort 
were treated according to the OT drug regimen used for MGH1528-1/2 discussed above. 
Tumor growth in response to OT therapy showed a range of values across all tested 
models thus minimizing the potential for floor or ceiling effects which would otherwise 
limit data driven conclusions. This range of responses included sensitive models (Best 
response: -100%, TTP: 80 days, TTP/Tdbl: 7.4) and resistant models (Best Response: 
+73%, TTP: 6 days, TTP/Tdbl: 0.9) with most models demonstrating an intermediate 
resistance phenotype (Table 3A-B) While PDX responses mirrored the available clinical 
data of best response and corrected TTP, there was not a significant difference in 
responses to OT between the EP-naive and EP exposed groups (Figure 6A). Furthermore, 
tumor metric data showed a weak trend between prior EP treatment of PDX models and 
OT treatment, suggesting that underlying mechanisms which differentiate EP-naïve and 
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EP-exposed groups may not have the same effect in the context of OT exposure for both 
PDXs and patients (Figure 6B). 
To better understand the evolution of models over the course of OT treatment, 
samples collected from the same subset of 19 models used in the EP cohort were 
examined for molecular pathways involved in tumor response. Full transcriptional 
analysis for the OT treated subset utilized the same Hallmark gene sets examined in the 
previous EP treatment analysis. Similar to the EP cohort, baseline gene expression 
models in the context of OT treatment were significantly correlated with treatment 
resistance but not treatment sensitivity.  Resistance-correlated transcripts revealed 
significant associations in genes involved in xenobiotic metabolism and glycolysis 
(Figure 6C). Detailed future investigation into which specific gene expression patterns 
mirrored differences in response data will help to narrow down the list of potential 
contributors of resistance; the process of which is currently underway. Interestingly, the 
xenobiotic metabolism and glycolysis gene sets as well as a small number of additional 
genes were also shown to be significantly correlated in the EP-treated cohort, suggesting 
that the resistance mechanisms underlying these transcriptional signatures may be shared 
between the two treatments.  The overlap of 31 genes between both groups comprised 
approximately 20% of all significantly upregulated genes in the OT cohort and 7.5% of 
all upregulated genes in the EP cohort (Figure 6D; Table 4). 
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DISCUSSION 
 
 
GENERATION OF PDX MODELS 
 
Current models for the study of SCLC such as cell lines and GEMMs have been 
shown to be limited in their ability to accurately translate research findings into clinical 
outcomes. While preliminary results from PDXs has shown increased potential for 
accurate disease modeling, this data until now has been minor in scope. The findings 
presented here demonstrate an efficient system for the collection of SCLC patient 
samples and ultimately PDX generation.   
The clinical management of SCLC severely limits access to direct sampling of 
patient tumors, presenting a significant barrier for the development of patient-derived 
models. As a means to bypass this complication, recent technologies have been 
developed to isolate CTCs from non-invasive blood draws. While limiting in the context 
of biopsy and surgical resection, the high rate of dissemination in SCLC presents a 
unique opportunity for collection of CTCs. For the development of PDXs presented here 
the majority of patient samples obtained relied heavily on the use of CTC-iChip 
technology to isolate CTCs at multiple critical timepoints. Xenograft models developed 
with tissue sourced from patient CTCs isolated via the CTC-iChip device had a success 
rate of 38% generating 16 established models. In addition to PDXs developed through 
blood draws, model generation was supplemented by tissue sourced from patient biopsies 
and effusions. Results from biopsies exhibited a success rate of 89% establishing 16 
models.  
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Comparative genome sequencing revealed that somatic mutational landscapes did 
not vary significantly between PDX models and clinical samples.  In addition, these 
models continued to maintain genomic stability throughout the early passages in mice. 
The nearly superimposable genomes between xenografts and their patient-derived tissue, 
as well as histological congruency, opens the possibility that PDX models of SCLC can 
represent specific patient tumors. PDXs have been used for study in various other 
cancers; however, the models established here represent the first extensive library of 
SCLC PDXs. This methodology also fosters the development of future SCLC PDX 
models outside of the MGH with the use of other commercially available microfluidic 
devices similar to the iChip-CTC setup utilized here.  
 
FUNCTIONAL FIDELITY OF PDXs 
 
For a new model system to be clinically relevant, it is important to demonstrate 
that the model system in question accurately recapitulates clinical disease progression.  
Standard of care treatment for SCLC relies most often on the anti-tumor DNA damaging 
agents Cisplatin/Etoposide. Approximately 60% of SCLC patients respond to this first 
line treatment to varying degrees until ultimately resistance emerges.  Demonstration of a 
functionally equivalent model system would therefore provide a platform not only to 
study underlying mechanisms of resistance but also to test novel therapeutic strategies. 
Here, a panel of 30 SCLC PDXs comprised of 12 EP-naïve and 18 EP-exposed 
models underwent treatment with a functional EP drug protocol.  It was observed that 
tumors derived from EP-naïve sources demonstrated significant response to drug 
treatment in a manner which mirrored patient responses. Additionally, treatment of mice 
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carrying tumors derived from EP-exposed sources had a wider range of response. This 
was not entirely unexpected given the varying degree to which resistance emerges in 
patients over the course of a fixed number of chemotherapy cycles. Tumor growth 
metrics, especially the corrected TTP measure, also showed significant differential 
response to EP between the EP-naïve and EP-exposed groups. This is the first time that 
statistically significant data has supported an accurate recapitulation of clinical responses 
in a PDX model system of SCLC in the context of first line chemotherapies. 
The ability of the SCLC PDX library to capture whether the donor patient had 
been exposed to first-line chemotherapy suggests that it may be able to recapitulate 
exposure histories to other experimental therapies. To test this, models obtained before 
and after patients went on the experimental treatment Olaparib/Temozolomide (OT) were 
generated.  Treatment with OT in models MGH1528-1 and MGH1528-2 revealed a sharp 
decline in tumor growth metrics in the OT-naïve model but not in the OT-exposed model. 
This initial probe mirrored patient tumor progression which suggested that, PDX 
responses may be able to accurately represent patient outcomes not only for EP but OT as 
well. To strengthen this hypothesis, four additional PDX models derived from 3 patients 
enrolled in the OT clinical trial were assessed and responses were found to correlate with 
the clinical histories of the donor patients. This limited subset of models is by no means 
definitive, yet the high genomic and histological fidelity of this in vivo system seems to 
indicate that the correlations between OT treatment of patients and PDXs presented here 
are unlikely to be functional outliers.  Provided additional experiments yield results in 
line with the current findings, it is reasonable to hope that SCLC PDX systems will 
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accurately recapitulate patient outcomes for a multitude of therapies. In the context of 
other currently used therapies such as the second line therapy Topotecan it would not 
unexpected to find that EP-naïve models would demonstrate sensitivity while Ep-exposed 
models would demonstrate resistance in a manner similar to EP treatment. 
 
MOLECULAR DETERMINANTS OF CHEMOTHERAPY RESISTANCE 
 
Drug-tested PDX tumor responses in combination with genomic fidelity of these 
in vivo models have provided significant evidence to suggest that this experimental setup 
is truly representative of SCLC tumors in their original clinical context.  However, the 
real power of this assessment is not limited to recapitulation of patient responses but also 
as a window of study aimed at examining patterns associated with chemoresistance.  A 
subset of 19 of these PDX models were chosen to undergo transcriptional analysis in the 
hopes of finding these relevant transcriptional signatures. As an important note, this 
subset of 19 models was chosen due to the established and drugged models available at 
the time of sequencing. This smaller subset is a limiting component of the analysis 
presented here and additional models for which EP response data has since been gathered 
would need to also be sequenced to further assure the conclusions of the data presented. 
Analysis of EP treated models revealed several expression patterns well correlated with 
EP resistance, among which MYC targets emerged as a top contender. Prior evidence has 
associated MYC overexpression as driver of EP resistance in GEMMs.54 In these studies, 
MYC expression increases the expression of a neuroendocrine profile through 
upregulation of Neurod1 and downregulation of ASCL1.  Similarly, EP resistance as 
qualified here in vivo demonstrates a similar dichotomous expression pattern of these two 
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factors lending further credibility to this gene set expression analysis. Furthermore, this is 
the first time that these findings in GEMMs has been corroborated in genomically and 
functionally equivalent patient-derived samples.  The molecular associations of EP 
resistance uncovered here also provide a baseline for which additional drug resistance 
patterns in SCLC can be compared. Given the clinically observed phenomenon of cross-
resistance, it would not be unexpected to see similar patterns of expression in cancers 
resistant to additional DNA damaging agents. 
 
CHEMOTHERAPY CROSS-RESISTANCE 
 
Clinical cross-resistance suggests that cellular mechanisms that permit relapse 
following first line therapy are also responsible for resistance to additional therapies. This 
may be due to similarity of mechanisms between first-line therapy and most second-line 
therapies: the generation of DNA damage. In addition, duration of response to first-line 
therapy is a good predictor of likelihood of response to second-line therapy. The 
functional in vivo model system outlined here allows for the interrogation of two 
important questions regarding this process. First, do models derived from EP resistant 
patients also demonstrate resistance to the novel OT therapy? Second, are the molecular 
pathways associated with EP resistance similarly correlated in OT-resistant models?  
 Previous investigation of tumor responses gleaned from the 30 model EP treated 
PDX cohort demonstrated a differential response between EP-naïve and EP-exposed 
models; however, it remained unclear whether this prior treatment status would similarly 
influence responses to novel chemotherapies. In parallel to EP treatment, the same set of 
30 models underwent OT treatment as part of a co-clinical phase I/II trial at MGH in the 
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hopes of finding biomarkers in response to this new therapy. Concurrently, this PDX 
testing also provided the opportunity to compare the responses to OT in EP-naïve and 
EP-exposed tumors. If significant cross-resistance were present, then models derived 
from patients following first-line therapy would be expected to be less responsive to OT 
treatment than EP-naïve models.  However, while the OT responses of these models 
accurately reflected patient response data where available, correlation between tumor 
response to EP versus OT showed only a weak trend towards significance. While some 
models showed resistance to OT, this was not necessarily connected to prior EP 
exposure.  The finding that models from pre-treated patients remain sensitive to OT gives 
hope that that the ongoing OT phase I/II trial may be effective in prolonging survival 
times in post-relapse patients.  
 There was a moderate correlation between EP and OT responses in the PDX 
models, suggesting that although history of EP exposure did not correlate with OT 
resistance, mechanisms underlying OT resistance may not be completely independent. To 
investigate this further, gene set enrichment analysis was performed same subset of 19 
models used for previous transcriptome analysis but this time assessed in the context OT-
treated response rates.  As with EP, this analysis showed correlation between OT 
resistance and associated expression of genes involved in xenobiotic metabolism and 
cellular glycolysis. This possibility is further corroborated by overlapping statistically 
significant increased expression of 31 genes in total.  Provided EP and OT response data 
were significantly correlated it would be expected that the 31 genes comprising 7.5% of 
EP genes and 20% of OT genes would be unexpectedly low.  However, since the 
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response data between the two cohorts showed only a weak trend towards correlation it is 
reasonable to expect that these may partially account for the incompletely independent 
resistance mechanisms.  
The combination of tumor metrics and gene expression profiles of the EP and OT 
treated models offers a number of potential theories behind the limited cross-resistance 
between the two, especially in the context of DNA damage. The mechanism of action of 
cisplatin involves the structural intra and inter crosslinking of DNA bases thereby 
creating kinks and ultimately damage to the DNA helical structure. At the same time 
Etoposide inhibits type II Topoisomerase by trapping it to DNA while undergoing its 
normal function reducing strain in DNA supercoils; a process which involves cleavage 
and reattachment of both DNA strands. The combination of Cisplatin and Etoposide 
provide anti-tumor effects by meaningfully damaging DNA in rapidly dividing cancer 
cells which are more sensitive to breaks in DNA structure. Although Olaparib and 
Temozolomide also cause DNA damage, the mechanism of cytotoxicity is significantly 
different. Temozolomide functions by methylating or alkylating DNA residues inhibiting 
normal function and ultimately leading to single-stranded breaks. In contrast, Olaparib 
acts on the DNA repair protein Poly ADP Ribose Polymerase (PARP) by “trapping” the 
protein to the DNA structure and preventing its normal function of DNA damage 
detection and recruitment of repair pathways.  Different mechanisms, and especially the 
addition of DNA repair inhibition with OT, may help explain why resistance mechanisms 
to one treatment may not overlap with resistance to the other.  
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The upregulation of xenobiotic mechanisms may be of significant interest in 
terms of drug resistance. Cellular xenobiotic metabolism concerns the enzymatic 
breakdown and expulsion of foreign drugs within the cell and has been implicated in 
resistance in multiple other cancers making it particularly relevant in this context. 
Overall, the common gene expression between the treated groups would seem to suggest 
that xenobiotic metabolism is a characteristic baseline feature of SCLC resistance.  
Interestingly, there are fewer pathways significantly upregulated at baseline in models 
experimentally found to be associated with OT resistance compared to EP resistance. 
This finding might suggest that while genes associated with xenobiotic metabolism may 
be advantageous in response to EP and OT treatment, additional genes such as the MYC 
associated genes may also be required for resistance in EP.  
Potential future avenues of testing may include experiments which further address 
the questions of underlying cross-resistance mechanisms.  While final results from 
ongoing clinical trials of OT are currently undetermined, post-relapse patients will 
continue to receive other DNA damaging agents such as the FDA approved second line 
therapy Topotecan.  The limited cross-resistance between EP and OT seen in PDX 
models should be compared to a context in which significant cross-resistance is expected.  
Testing PDX models with Topotecan and examining tumor metrics and gene expression 
as previously done in EP and OT cohorts may help to determine the form of cross-
resistance more typically seen in the clinical setting. A further area of exploration might 
also be the targeting of factors which have been shown to be associated with drug 
resistance in both EP and OT. It is worth noting that one particular gene significantly 
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upregulated in both groups, CUL4A is an E3 ubiquitin ligase with multiple cellular 
targets and may in fact play a role in DNA damage repair.  A number of reports have 
shown that CUL4A plays a role in other cancers, is a necessary component for DNA 
repair, and its low expression levels are correlated with cisplatin sensitivity.55-56 
Presumably, high expression of CUL4A would yield an increased breakdown of 
chemotherapeutic agents and thereby limit the DNA damaging effects on drugs such as 
Cisplatin. Gene expression data here demonstrates this high expression of CUL4A as a 
marker of cisplatin resistance, supporting prior literature.  The CUL4A ubiquitin ligase 
has been previously associated with cisplatin sensitivity when expressed at low levels and 
other studies have used a known inhibitor of this protein to induce tumor cell death.56 An 
in vivo study which sought to give this inhibitor (MLN4924) in concurrence with EP or 
OT presents an opportunity to nullify a significant influence in drug resistance.  
 In summary, the study presented here outlines the development of a library of 
SCLC PDX models which have demonstrated both functional and genomic fidelity. 
Models treated with first line chemotherapy EP provided a basis for evaluation of 
treatment with the novel chemotherapy OT. Comparison of tumor metrics and gene 
expression patterns between the two groups revealed incomplete independent 
mechanisms of chemotherapy resistance. The methodology behind the findings harbors 
the potential for further comparison with additional chemotherapy treatment in both 
testing of novel agents and investigation of the elusive underpinnings of cross-resistance 
in SCLC.  
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